Brazilian Single-Center Experience with Aortic Root Replacement in 448 Patients: What is the Best Technique?

Fabrício José Dinato1, MD; Ricardo Ribeiro Dias1, MD, PhD; José Augusto Duncan1, MD; Fábio Fernandes2, MD; Felix José Alvares Ramirez2, MD; Charles Mady2, MD; Fabio B Jatene1, MD, PhD

Abstract

Introduction: The objective of this study was to evaluate whether a surgery with the use of valved conduit is capable of leading to better immediate and late results than those obtained by the valve-sparing aortic root reconstruction technique.

Methods: Between January 2002 and June 2016, 448 patients underwent aortic root reconstruction. These were divided into three groups according to the technique used: 319 (71.2%) patients received mechanical valved conduits, 49 (10.9%) received biological valved conduits, and 80 (17.9%) underwent the valve-sparing aortic root reconstruction technique. The results were examined by univariate and multivariate analyses of Cox proportional hazards models with multiple logistic regression.

Results: The hospital mortality rate was 7.5%. The mortality rates were 8.2%, 12%, and 2.5% in the mechanical valved conduit, biological valved conduit, and aortic valve-sparing groups, respectively, with no significant difference between groups (P=0.1). Thromboembolic complications and reoperation-free survival were also similar (P=0.169 and P=0.688). However, valve-sparing aortic root replacement was superior in terms of long-term survival (P<0.001), hemorrhagic-free survival (P<0.001), and endocarditis-free survival (P=0.048). Multivariate analysis showed that the following aspects had an impact on mortality: age > 70 years (P<0.001; hazard ratio [HR] 1.05), preoperative acute kidney injury (P<0.0042; HR 2.9), diagnosis of dissection (P<0.01; HR 2.0), previous cardiac surgery (P<0.027; HR 2.3), associated coronary artery bypass grafting (P<0.038; HR 1.8), reoperation for postoperative tamponade (P<0.004; HR 2.2) and postoperative acute kidney injury (P<0.02; HR 3.35).

Conclusion: Valve-sparing technique seems to be the operation of choice, whenever possible, for aortic root reconstruction.

Keywords: Aorta. Aortic Diseases. Thoracic. Cardiac Surgical Procedures. Aortic Valve.

1Department of Cardiovascular Surgery, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
2Clinical Unit of Myocardiopathies and Aortic Diseases, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

This study was carried out at the Department of Cardiovascular Surgery, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

DOI: 10.21470/1678-9741-2020-0043

Abbreviations, acronyms & symbols

| AD | = Aortic dissection |
| AMI | = Acute myocardial infarction |
| AR | = Aortic regurgitation |
| ARF | = Acute renal failure |
| ARR | = Aortic root replacement |
| AS | = Aortic stenosis |
| BMI | = Body mass index |
| CABG | = Coronary artery bypass grafting |
| CI | = Confidence interval |
| COPD | = Chronic obstructive pulmonary disease |
| CPB | = Cardiopulmonary bypass |
| FC | = Functional class (New York Heart Association) |
| HIV | = Human immunodeficiency virus |
| HR | = Hazard ratio |
| MI | = Myocardial infarction |
| MVS | = Mitral valve surgery |
| RF | = Renal failure |
| SD | = Standard deviation |

Correspondence Address:
Fabrício José Dinato
https://orcid.org/0000-0003-1729-4685
Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Av. Dr. Enéas de Carvalho Aguiar, 44 – Pinheiros, São Paulo, SP, Brazil
Zip Code: 05403900
E-mail: fabrijoedinato@incor.usp.br

Article received on January 28th, 2020.
Article accepted on March 21st, 2020.
INTRODUCTION

Aortic root replacement (ARR) surgery using a valved conduit, whether mechanical or biological, is still the most commonly used technique for the correction of diseases affecting this aortic segment\[1\]. Although mechanical valves are traditionally used, these prosthesis expose patients to risks of complications related to thromboembolism and anticoagulation, in addition to infectious complications, which also occur with biological valved conduits.

Since the introduction of biological valved conduits by Griepp et al.\[2\] in the 1990s, these conduits are available and avoid the adverse effects of prolonged anticoagulation. However, despite the longer durability of the new generation of bioprostheses available, there is a concern regarding the degeneration of the biological valve prostheses and the need for complex reoperation, which justifies the formal indication according to international guidelines in patients older than 70 years of age\[3\].

Excellent results from valve-sparing ARR techniques have been widely published in recent years\[4\]. However, the complexity of the procedure and the need for adequate patient selection according to valvular pathology still limit this procedure for correction of aortic root diseases.

Through analysis of the results of different ARR techniques, the objective of this study was to evaluate whether operations involving the use of valved conduits lead to better immediate and late results than those obtained by the valve-sparing ARR technique.

METHODS

From January 2002 to June 2016, 448 patients underwent ARR surgery. They were divided into three groups according to the ARR technique used: 319 (71.2%) patients underwent surgery using a mechanical valved conduit, 49 (10.94%) received a biological valved conduit, and 80 (17.86%) patients underwent ARR surgery with aortic valve preservation through the reimplantation technique.

Data were obtained through retrospective analysis of a prospectively constructed database from the Aorta Group of the Instituto do Coração – InCor, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. The patients who were not followed up at the institution were evaluated through telephone contact. The study was approved by the institution’s scientific and ethics committee and written consent from the patients was not required due to the characteristics of the study.

Three hundred seventy-two (83%) patients underwent aneurysm surgery, and 76 (17%) underwent chronic aortic dissection surgery. The mean patient age was 55 years, and 330 (73.66%) patients were men. The demographic characteristics of the patients under study are listed in Table 1. Patients with acute dissection were excluded from the study. Late follow-up was performed in 86% of the patients.

The indications for surgical treatment of aortic root diseases were in accordance with the last American and European guidelines of 2010 and 2014\[5,6\], respectively. The operative technique used for ARR with either a mechanical or a biological valve conduit was performed using the modified Bentall procedure. The aorta was transected at the sinotubular junction and the coronary ostia excised with a cuff of aortic wall. The aortic root and valve were excised and then replaced by suture of a valvar conduit onto the annulus with the use of interrupted pledged polyester 2-0 suture. The coronary ostia were reimplemented and the distal aorta was anastomosed.

A self-made biological composite graft was chosen for those older than 60 years of age and those in whom anticoagulation was contraindicated. After measuring the aortic annulus size and selecting the appropriate-size valve prosthesis, the biological valve was sutured intraoperatively with the vascular conduit using three single polypropylene sutures.

The reimplantation technique (David III procedure)\[7\] was performed in patients without significant valvular regurgitation, those with valvular regurgitation secondary to annular dilatation, and those with valve regurgitation due to prolapse of one or more leaflets susceptible to plasty. The valve-sparing procedure was performed with the dissection of the aortic root as low as possible. Commissural traction stitches were applied, and the left and right coronary buttons were prepared. The aortic sinuses were resected preserving a 3-5 mm rim of aortic wall just above the annulus alongside each of the three commissures. Three subcommissural 2-0 polyester sutures from inside to outside were placed below the aortic annulus and more three 2-0 polyester stitches were placed from inside to outside just below the nadir leaflet insertion. These sutures were passed through the base of the vascular prosthesis respecting their proximal positioning. Then a 4-0 polypropylene running suture for valve reimplantation was performed passing the suture from outside the prosthesis to inside and through the aortic wall, staying close to the annulus, and then back out of the prosthesis. Coronary reimplantation was performed with a 5-0 polypropylene running suture and darts were placed between each commissure to create bulges in the graft. The intraoperative characteristics are listed in Table 2.

The results analyzed were hospital complications and mortality, endocarditis-free survival, hemorrhagic and thromboembolic complication-free survival, reoperation-free survival, and late survival.

The follow-up time ranged from one month to 11 years, with an average of 2.63 years. When we analyzed the groups separately, the mean follow-up time of the groups of patients who underwent ARR with valve-sparing, mechanical, and biological valved conduits was 3.5, 2.5, and 1.6 years, respectively.

Statistical Analysis

For the data analysis, continuous variables are expressed as the mean ± standard deviation and categorical variables are described as percentages. Continuous variables were analyzed using the nonparametric Kruskal-Wallis test. The chi-square test and Fisher’s exact test, when appropriate, were used to analyze the categorical variables. The univariate and multivariate analyses of Cox proportional hazards models were used to study the associations between risk factors and survival, and multiple logistic regression was performed through the stepwise selection process. Survival curves and event-free survival curves
Table 1. Patients' characteristics.

| Variables                              | Biological composite graft (n=49) | Mechanical composite graft (n=319) | Valve-sparing technique (n=80) | P-value |
|----------------------------------------|-----------------------------------|-----------------------------------|-------------------------------|---------|
| Mean age, years (mean ± SD)            | 68.5±12.0                         | 54.2±14.2                         | 51.4±16.6                     | < 0.001 |
| Male, n (%)                            | 36 (73.5)                         | 236 (74.0)                        | 58 (72.5)                     | 0.964   |
| BMI, kg/m² (mean ± SD)                 | 26.2±4.8                          | 26.5±4.7                          | 25.5 ± 4.6                    | 0.375   |
| Hypertension, n (%)                    | 39 (76.0)                         | 206 (64.6)                        | 58 (72.5)                     | 0.066   |
| Diabetes mellitus, n (%)               | 8 (16.3)                          | 28 (8.8)                          | 7 (8.8)                       | 0.238   |
| Dyslipidemia, n (%)                    | 17 (34.7)                         | 70 (21.9)                         | 17 (21.3)                     | 0.130   |
| Chronic RF, n (%)                      | 14 (28.6)                         | 29 (9.1)                          | 7 (8.8)                       | < 0.001 |
| Acute RF, n (%)                        | 1 (2.0)                           | 8 (2.5)                           | 2 (2.5)                       | 1       |
| Smoking, n (%)                         | 26 (53.0)                         | 99 (31.0)                         | 33 (41.3)                     | 0.005   |
| COPD, n (%)                            | 11 (22.5)                         | 26 (8.2)                          | 5 (6.3)                       | 0.003   |
| Family history, n (%)                  | 2 (4.1)                           | 25 (7.8)                          | 6 (7.5)                       | 0.644   |
| Dyspepsia, n (%)                       | 5 (10.2)                          | 24 (7.5)                          | 8 (10.0)                      | 0.673   |
| Stroke with sequel, n (%)              | 0 (0.0)                           | 4 (1.3)                           | 1 (1.3)                       | 1       |
| Stroke without sequel, n (%)           | 2 (4.1)                           | 12 (3.8)                          | 0 (0.0)                       | 0.185   |
| HIV, n (%)                             | 0 (0.0)                           | 5 (1.6)                           | 0 (0.0)                       | 0.770   |
| Cancer, n (%)                          | 4 (8.2)                           | 6 (1.9)                           | 2 (2.5)                       | 0.494   |
| Coronary insufficiency, n (%)          | 17 (34.7)                         | 51 (16.0)                         | 15 (18.8)                     | 0.007   |
| Prior MI, n (%)                        | 5 (10.2)                          | 16 (5.0)                          | 2 (2.5)                       | 0.163   |
| Reoperation, n (%)                     | 6 (12.2)                          | 86 (27.1)                         | 2 (2.5)                       | < 0.001 |
| Chest pain, n (%)                      | 15 (30.6)                         | 101 (31.7)                        | 28 (35.0)                     | 0.825   |
| Prior atrial fibrillation, n (%)       | 8 (16.3)                          | 49 (15.4)                         | 3 (3.8)                       | 0.021   |
| Marfan syndrome, n (%)                 | 2 (4.1)                           | 21 (6.6)                          | 13 (16.3)                     | 0.010   |
| Bicuspid aortic valve, n (%)           | 13 (26.5)                         | 59 (18.5)                         | 8 (10.0)                      | 0.051   |
| Ejection fraction, (mean ± SD)         | 0.55±0.12                         | 0.58±0.12                         | 0.59±0.09                     | 0.215   |
| Aortic diameter, mm (mean ± SD)        | 54.9±7.3                          | 58.5±11.2                         | 54.4±8.9                      | 0.002   |
| Aortic regurgitation, n (%)            |                                   |                                   |                               | 0.301   |
| Moderate/severe AR, n (%)              | 39 (81.3)                         | 232 (73.4)                        | 55 (18.8)                     |         |
| Aortic stenosis, n (%)                 |                                   |                                   |                               | 0.013   |
| Moderate/severe AS, n (%)              | 3 (6.3)                           | 12 (3.7)                          | 0 (0.0)                       |         |
| Cardiac insufficiency, n (%)           |                                   |                                   |                               |         |
| FC III/IV, n (%)                       | 18 (36.7)                         | 83 (26.1)                         | 7 (8.8)                       | < 0.001 |
| Indication for surgery, n (%)          |                                   |                                   |                               | 0.347   |
| Aneurysm, n (%)                        | 45 (93.9)                         | 251 (79.0)                        | 76 (95.0)                     | < 0.001 |
| Type A chronic AD, n (%)               | 3 (6.1)                           | 68 (21.3)                         | 5 (6.3)                       | < 0.001 |

AD=aortic dissection; AR=aortic regurgitation; AS=aortic stenosis; BMI=body mass index; COPD=chronic obstructive pulmonary disease; FC=functional class (New York Heart Association); HIV=human immunodeficiency virus; MI=myocardial infarction; RF=renal failure; SD=standard deviation
were estimated using the Kaplan-Meier method and the log-rank test. \( P<0.05 \) was considered statistically significant.

**RESULTS**

The overall hospital mortality rate was 7.5%. The hospital mortality rate was 8.2% (26/319) in the group of patients who underwent ARR with a mechanical valve conduit, 12% (6/49) in the group of patients who underwent ARR with a biological valve conduit, and 2.5% (2/80) in the valve-sparing ARR group, with no significant difference between the groups (\( P=0.1 \)).

Hospital deaths were due to low cardiac output in 10 (2.2%) patients, hemorrhagic shock in eight (1.78%) patients, pneumonia in five (1.1%) patients, low cardiac output associated with sepsis in four (0.9%) patients, septic shock in three (0.66%) patients, mediastinitis in two (0.45%) patients, mesenteric ischemia in one (0.22%) patient, and one (0.22%) patient died for unknown reasons. In terms of hospital complications, low cardiac output was the only hospital complication that was different between the groups (\( P=0.014 \)). Cardiac output was significantly better in the group in which the valve was preserved, despite the longer cardiopulmonary bypass duration and myocardial ischemia time required to perform the procedure (Table 3).

When late survival was evaluated, the group of patients who underwent valve-sparing ARR had longer survival (97%) during the follow-up period (\( P<0.001 \)) (Figure 1). The median-term and the one-year survival rates of the entire cohort was 68.8% (58.2% - 79.4% 95% confidence interval [CI]) and 88.3% (85.1% - 91.5% 95% CI), respectively (\( P<0.001 \)) (Table 4).

| Variables                          | Biological composite graft (n=49) | Mechanical composite graft (n=319) | Valve-sparing technique (n=80) | \( P \)-value |
|------------------------------------|----------------------------------|----------------------------------|-------------------------------|--------------|
| CPB time, min (mean ± SD)         | 125.7±26.5                       | 134.0±35.0                       | 166.5±28.4                    | < 0.001      |
| Myocardial ischaemic time, min     | 103.4±22.3                       | 108.0±27.4                       | 144.7±23.3                    | < 0.001      |
| (mean ± SD)                        |                                  |                                  |                               |              |
| Associated procedures, n (%)       |                                 |                                  |                               |              |
| CABG, n (%)                        | 11 (22.5)                        | 39 (12.2)                        | 7 (8.8)                       | 0.068        |
| MVS, n (%)                         | 7 (14.3)                         | 18 (5.6)                         | 6 (7.5)                       | 0.083        |
| Stent grafting via aortic arch, n (%) | 1 (2.0)                          | 19 (6.0)                         | 3 (3.8)                       | 0.614        |

CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass; MVS=mitral valve surgery; SD=standard deviation

---

**Fig. 1** – Survival curves of patients undergoing aortic root replacement surgery using mechanical and biological valved conduits and with valve-sparing techniques.
Table 3. Postoperative complications.

| Variables                                | Biological composite graft (n=49) | Mechanical composite graft (n=319) | Valve-sparing technique (n=80) | P-value |
|------------------------------------------|----------------------------------|-----------------------------------|-------------------------------|---------|
| Re-exploration for bleeding, n (%)       | 9 (11.4)                         | 6 (15.4)                          | 3 (7.5)                       | 0.311   |
| Low cardiac output, n (%)                | 8 (10.1)                         | 8 (20.5)                          | 0 (0.0)                       | 0.002   |
| Wound infection, n (%)                   | 8 (10.1)                         | 3 (7.7)                           | 5 (12.5)                      | 0.712   |
| Mediastinitis, n (%)                     | 1 (1.3)                          | 0 (0.0)                           | 1 (2.5)                       | 1       |
| Pneumonia, n (%)                         | 22 (27.9)                        | 7 (18.0)                          | 15 (37.5)                     | 0.053   |
| Urinary tract infection, n (%)           | 10 (12.7)                        | 4 (10.3)                          | 6 (15.0)                      | 0.737   |
| Sepsis, n (%)                            | 19 (24.1)                        | 10 (25.6)                         | 9 (22.5)                      | 0.744   |
| Prolonged mechanical ventilation, n (%)  | 7 (8.9)                          | 4 (10.3)                          | 3 (7.5)                       | 0.712   |
| ARF without dialysis, n (%)              | 31 (39.2)                        | 10 (25.6)                         | 21 (52.5)                     | 0.015   |
| ARF with dialysis, n (%)                 | 6 (7.6)                          | 3 (7.7)                           | 3 (7.5)                       | 1       |
| Delirium, n (%)                          | 3 (3.8)                          | 1 (2.6)                           | 2 (5.0)                       | 1       |
| Stroke (permanent deficit), n (%)        | 4 (5.1)                          | 1 (2.6)                           | 3 (7.5)                       | 0.615   |
| Spinal cord injury, n (%)                | 2 (2.5)                          | 2 (5.1)                           | 0 (0.0)                       | 0.241   |
| AML, n (%)                               | 2 (2.5)                          | 1 (2.6)                           | 1 (2.5)                       | 1       |
| Atrial arrhythmias, n (%)                | 17 (21.5)                        | 8 (20.5)                          | 9 (22.5)                      | 0.830   |
| In-hospital mortality, n (%)             | 16 (20.3)                        | 12 (30.8)                         | 4 (10.0)                      | 0.022   |

AMI=acute myocardial infarction; ARF=acute renal failure

Table 4. Survival rates.

| Techniques          | Median-term survival rate (95% CI) | One-year survival rate (95% CI) | P<0.001 |
|---------------------|-----------------------------------|---------------------------------|---------|
| Entire cohort       | 68.8% (58.2 - 79.4%)              | 88.3% (85.1 - 91.5%)            |         |
| Biological composite graft | 68.3% (48.3 - 88.3%)               | 80.9% (69.3 - 92.5%)            |         |
| Mechanical composite graft | 61.4% (47.6 - 75.2%)              | 87% (83 - 91%)                  |         |
| Valve-sparing technique | 97.5% (93.9 - 100%)               | 97.5% (93.9 - 100%)             |         |

CI=confidence interval

Regarding the reoperation-free survival, similar behavior was observed between the groups, demonstrating that aortic valve preservation was not associated with a greater need for reoperation during the follow-up period (P=0.688) (Figure 2).

Concerning hemorrhagic complications, there was a difference between the groups. The rate of hemorrhagic complications was significantly higher in the group of patients treated with a mechanical valve conduit (P<0.001). These complications occurred in 10% of the patients (32/319), and in 1.9% of the patients (6/319) they were the cause of death (two patients died of hemorrhagic stroke, two patients died of upper gastrointestinal bleeding, one patient died of cardiac tamponade, and one patient died of a spinal cord hematoma) (Figure 3).

There was no difference in thromboembolic complications during the follow-up period, as shown in Figure 4 (P=0.169).

The occurrence of late endocarditis was lower in the group in which the aortic valve was preserved (P=0.048). Of the 10 patients affected (all of whom underwent ARR with a valved conduit), 60% required surgery (Figure 5).

The multivariate analysis showed that the following factors had an impact on mortality: age > 70 years, with a hazard ratio (HR) of 1.05 (P<0.0001); preoperative acute kidney injury, with a HR of 2.9 (P<0.0042); diagnosis of dissection, with a HR of 2.0 (P<0.01); history of previous cardiac surgery, with a HR of 2.3 (P<0.027); need for associated coronary artery bypass grafting, with a HR of 1.8 (P<0.038); need for reoperation for postoperative...
tamponade, with a HR of 2.2 (P<0.004); and acute kidney injury during the postoperative period, with a HR of 3.35 (P<0.02).

**DISCUSSION**

ARR using valved conduits for treatment of aortic root diseases presents a low mortality rate and good long-term results. The overall operative mortality (death within 30 days of surgery) of ARR with valved conduits in recent publications varies from 0.7% to 11%, with survival rates ranging from 76% to 91.8% in five years and 62% to 76% in 10 years[8]. However, in recent years, several series have shown that valve-sparing ARR is an interesting alternative for patients with normal or slightly altered aortic valve leaflets, with a reoperation-free survival rate of 94% to 97% of patients[8].
David et al.\[9\] published a study of 151 patients who underwent valve-sparing ARR in patients with aneurysms of the aortic root and reported 99.1% aortic valve reoperation-free survival when the reimplantation technique was used and 83% late survival for patients with root aneurysms at eight years of follow-up. Dias et al.\[10\] presented the results of 78 patients who underwent valve-sparing ARR during a follow-up period of 1621±1156 days. When comparing patients who underwent aortic valve repair with those who did not undergo this procedure, they observed that aortic valve repair did not increase the risk of reoperation of the valve and was a very safe and long-lasting approach.

In this study, we presented the results of our experience in ARR and despite the difference between the groups, we compared the ARR techniques with valved conduits (mechanical or biological) and the valve-sparing reimplantation technique. Our data indicated 96.5% freedom from reoperation in valve-sparing group.
during follow-up, with only two patients indicated for aortic valve approach, demonstrating that aortic valve preservation was not associated with a greater need for reoperation. Actually, in this study, we observed that valve sparing aortic root reimplantation, when feasible, is an excellent alternative to composite conduits with mechanical or bioprostheses, with favorable short and medium-term outcomes.

Although the classic technique uses mechanical valved conduits, tubes constructed with biological prostheses have also presented good results. Etz et al.\[1]\) published a series of 275 patients, with a mean age of 69 years, who underwent ARR surgery with biological valved conduits and found a hospital mortality of 6.2% and a need for reoperation due to structural deterioration of the prosthesis in only one patient (0.4%) 12 years after surgery. Lehr et al.\[2]\) reported a study of 144 patients who underwent ARR surgery and compared the results between the use of mechanical and biological valved conduits. They described an operative mortality of 2.1%; one- and five-year survival rates for the mechanical group were 96.0% and 89.0%, respectively, vs. 93.0% and 84.0% for the biological group, concluding that mortality rate and complications related to the type of prosthesis used were similar in both groups at five years of follow-up.

In our experience, we found a significantly lower rate of hemorrhagic complications in the group of patients treated with biological valved conduit, with similar rate of endocarditis between mechanical and biological valve prosthesis. In addition, at the present study, we demonstrated a similar hospital mortality and overall probability of survival for patients with mechanical and biological composite grafts, although without an age-matched population analysis. Therefore, ARR with a biological valve seems to be an excellent alternative for those with contraindications for anticoagulation or older patients, since they are associated with low probabilities of structural prosthesis deterioration and need for reoperation, in addition to low rates of hemorrhagic or thromboembolic complications compared with mechanical valves. Besides, biological valved conduits have become an attractive option to consider in cases of posterior transcatheter valve-in-valve implantation, which is increasingly considered in clinical practice.

Gaudino et al.\[3]\) published a series of 890 patients who underwent ARR with a mechanical composite valved graft, biological composite valved graft, or a valve-sparing reconstruction. Their operative mortality was 0.2%, five-year survival was 89.4% and, in the propensity-matched groups, the type of operation performed did not affect in-hospital and late outcomes.

In our study, during the follow-up period, valve-sparing ARR was superior to the other techniques in terms of long-term survival, freedom from hemorrhagic complications, and freedom from endocarditis, and there was no difference between ARR techniques regarding the need for reoperation.

Karck et al.\[4]\) in a series of 119 patients with Marfan syndrome, compared composite graft replacement with mechanical valve conduits and aortic valve-sparing reimplantation and demonstrated freedom from reoperation and death after one year of 97% and 97% for ARR with mechanical valved conduit and 95% and 100% for valve-sparing by reimplantation technique, with no significant difference between groups. Although similar survival contrasts with our results, they also showed lower risk of bleeding complications in the valve-sparing group and similar freedom from reoperation.

Svensson et al.\[5]\) described a large single-institution series of 957 patients who underwent four aortic root procedures and showed less risk of valve-related complications, such as bleeding and endocarditis, and lowest late risk of reoperation in the valve-sparing group in a follow-up of 5.3 years. They also described a worst survival rate in patients who underwent biological composite graft ARR, probably due to differences in patients’ characteristics.

Similarly, it must be noted that although we found a superior long term-survival in the valve-sparing group, any difference in survival can be attributed to differences in patient demographic characteristics, particularly age, prevalence of comorbidities and aortic pathology.

Most risk factors for mortality in our multivariate analysis were related with age, preoperative and postoperative acute kidney injury, prior cardiac surgery, a diagnosis of dissection, coronary artery bypass grafting associated with aortic surgery, and postoperative tamponade, and we strongly believe that mortality rate is influenced by an amount of co-morbidities rather than the surgical technique.

Furthermore, despite the superior results observed for valve-sparing ARR technique during the follow-up period, mainly for younger patients with aortic root aneurysm and aortic valve regurgitation with normal leaflets or susceptible plasty, it must be mentioned that, for those surgeons who are not familiar with valve-sparing operation, ARR with composite conduits is certainly still a valuable option. In addition, the valve-sparing ARR technique is not feasible for all patients because of compromised leaflets. However, whenever possible, the best late survival achieved with valve preservation needs to be considered, and surgeons should be prepared to perform this procedure.

**Limitations**

We must highlight some limitations of this study. Mainly, because it was a retrospective study in which randomization for the aortic root reconstruction technique applied was not possible. In addition, the study had a short postoperative follow-up time and the groups were not completely similar. The short follow-up time was due to the fact that a greater number of patients was operated few years before and loss of follow-up occurred regarding patients undergoing surgery at the beginning of the study period.

**CONCLUSION**

Due to the limitations mentioned above, it was not possible to definitively clarify which technique is the best for ARR. However, according to our results, we can conclude that the valve-sparing technique seems to be the operation of choice, whenever possible, for ARR.

No financial support.

No conflict of interest.
Authors' roles & responsibilities

FJD Substantial contributions to the conception or design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published

RRD Substantial contributions to the conception or design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published

JAD Substantial contributions to the conception or design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published

FF Agreement to be accountable for all aspects of the work in ensuring that issues related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published

FJAR Agreement to be accountable for all aspects of the work in ensuring that issues related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published

CM Agreement to be accountable for all aspects of the work in ensuring that issues related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published

FBJ Agreement to be accountable for all aspects of the work in ensuring that issues related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published

REFERENCES

1. Etz CD, Bischoff MS, Bodian C, Roder F, Brenner R, Grieppe RB, et al. The Bentall procedure: is it the gold standard? A series of 597 consecutive cases. J Thorac Cardiovasc Surg. 2010;140(6 Suppl):S64-70; discussion S86-91. doi:10.1016/j.jtcvs.2010.07.033.

2. Galla JD, Lansman SL, Spielvogel D, Minanov OP, Ergin MA, Bodian CA, et al. Bioprosthetic valved conduit aortic root reconstruction: the Mount Sinai experience. Ann Thorac Surg. 2002;74(5):S1769-72; discussion S1792-9. doi:10.1016/s0003-4975(02)04144-9.

3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/AHA ACC focused update of the 2014 AHA/AHA ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70(2):252-89. doi:10.1016/j.jacc.2017.03.011.

4. Dias RR, Mejia OA, Fiorelli AI, Pomerantzfeff PM, Dias AR, Mady C, et al. Analysis of aortic root surgery with composite mechanical aortic valve conduit and valve-sparing reconstruction. Rev Bras Cir Cardiovasc. 2010;25(4):491-9. doi:10.1590/S0102-76382010000400012.

5. Hirata LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AATS/ACR/ASA/SCA/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, American association for thoracic surgery, American college of radiology, American stroke association, society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, society of interventional radiology, society of thoracic surgeons, and society for vascular medicine. Circulation. 2010;121(13):e266-369. Erratum in: Circulation. 2010;122(4):e410. doi:10.1161/CIRC0B.113.318134739e.

6. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European society of cardiology (ESC). Eur Heart J. 2014;35(41):2873-926. Erratum in: Eur Heart J. 2015;36(41):2779. doi:10.1093/eurheartj/ehu281.

7. David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg. 1992;103(4):617-21; discussion 622.

8. Ehrlich MP, Ergin MA, McCullough JN, Lansman SL, Galla JD, Bodian CA, et al. Favorable outcome after composite valve-graft replacement in patients older than 65 years. Ann Thorac Surg. 2001;71(5):1454-9. doi:10.1016/s0003-4975(01)02405-5.

9. David TE, Ivanov J, Armstrong S, Feindel CM, Webb GD. Aortic valve-sparing operations in patients with aneurysms of the aortic root or ascending aorta. Ann Thorac Surg. 2002;74(5):S1758-61; discussion S1792-9. doi:10.1016/s0003-4975(02)04135-8.

10. Dias RR, Duncan JA, de Souza Dinato FJ, Araújo LL, Issa HMN, Fernandes F, et al. Aortic root reconstruction with a bioprosthetic valved conduit: a consecutive series of 275 procedures. J Thorac Cardiovasc Surg. 2007;133(6):1455-63. doi:10.1016/j.jtcvs.2007.01.058.

11. Lehrl EJ, Wang PZ, Orepoulos A, Kanji H, Norris C, Macarthur R. Midterm outcomes and quality of life of aortic root replacement: mechanical vs biological conduits. Can J Cardiol. 2011;27(2):207-12. doi:10.1016/j.cja.2011.07.034.

12. Gaudino M, Lau C, Munjal M, Avgerinos D, Girardi LN. Contemporary outcomes of surgery for aortic root aneurysms: comparison of valve-sparing and composite valve graft replacement. J Thorac Cardiovasc Surg. 2015;150(5):1120-9.e1. doi:10.1016/j.jtcvs.2015.07.015.

13. Karck M, Kallenbach K, Hagl C, Rhein C, Leyh R, Haverich A. Aortic root surgery in Marfan syndrome: comparison of aortic valve-sparing reimplantation versus composite grafting. J Thorac Cardiovasc Surg. 2004;127(2):391-8. doi:10.1016/j.jtcvs.2003.07.049.

14. Svensson LG, Pillai ST, Rajeswaran J, Desai MY, Griffin B, Grimm R, et al. Long-term survival, valve durability, and reoperation for 4 aortic root procedures combined with ascending aorta replacement. J Thorac Cardiovasc Surg. 2016;151(3):764-74.e4. doi:10.1016/j.jtcvs.2015.10.113.